207 related articles for article (PubMed ID: 37390209)
1. Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness.
Oropeza E; Seker S; Carrel S; Mazumder A; Lozano D; Jimenez A; VandenHeuvel SN; Noltensmeyer DA; Punturi NB; Lei JT; Lim B; Waltz SE; Raghavan SA; Bainbridge MN; Haricharan S
Sci Adv; 2023 Jun; 9(26):eadf2860. PubMed ID: 37390209
[TBL] [Abstract][Full Text] [Related]
2. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
[TBL] [Abstract][Full Text] [Related]
3. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
[TBL] [Abstract][Full Text] [Related]
4. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.
Haricharan S; Punturi N; Singh P; Holloway KR; Anurag M; Schmelz J; Schmidt C; Lei JT; Suman V; Hunt K; Olson JA; Hoog J; Li S; Huang S; Edwards DP; Kavuri SM; Bainbridge MN; Ma CX; Ellis MJ
Cancer Discov; 2017 Oct; 7(10):1168-1183. PubMed ID: 28801307
[TBL] [Abstract][Full Text] [Related]
5. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
6. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Determinants of Response to HER Kinase Inhibition in
Smyth LM; Piha-Paul SA; Won HH; Schram AM; Saura C; Loi S; Lu J; Shapiro GI; Juric D; Mayer IA; Arteaga CL; de la Fuente MI; Brufksy AM; Spanggaard I; Mau-Sørensen M; Arnedos M; Moreno V; Boni V; Sohn J; Schwartzberg LS; Gonzàlez-Farré X; Cervantes A; Bidard FC; Gorelick AN; Lanman RB; Nagy RJ; Ulaner GA; Chandarlapaty S; Jhaveri K; Gavrila EI; Zimel C; Selcuklu SD; Melcer M; Samoila A; Cai Y; Scaltriti M; Mann G; Xu F; Eli LD; Dujka M; Lalani AS; Bryce R; Baselga J; Taylor BS; Solit DB; Meric-Bernstam F; Hyman DM
Cancer Discov; 2020 Feb; 10(2):198-213. PubMed ID: 31806627
[No Abstract] [Full Text] [Related]
8. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
[TBL] [Abstract][Full Text] [Related]
9. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.
Salazar MD; Ratnam M; Patki M; Kisovic I; Trumbly R; Iman M; Ratnam M
Breast Cancer Res; 2011 Feb; 13(1):R18. PubMed ID: 21299862
[TBL] [Abstract][Full Text] [Related]
10. Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.
Hagio K; Amano T; Hayashi H; Takeshita T; Oshino T; Kikuchi J; Ohhara Y; Yabe I; Kinoshita I; Nishihara H; Yamashita H
Sci Rep; 2021 Apr; 11(1):8109. PubMed ID: 33854152
[TBL] [Abstract][Full Text] [Related]
11. Combined Blockade of Activating
Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
[TBL] [Abstract][Full Text] [Related]
12. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III
Ma CX; Suman V; Goetz MP; Northfelt D; Burkard ME; Ademuyiwa F; Naughton M; Margenthaler J; Aft R; Gray R; Tevaarwerk A; Wilke L; Haddad T; Moynihan T; Loprinzi C; Hieken T; Barnell EK; Skidmore ZL; Feng YY; Krysiak K; Hoog J; Guo Z; Nehring L; Wisinski KB; Mardis E; Hagemann IS; Vij K; Sanati S; Al-Kateb H; Griffith OL; Griffith M; Doyle L; Erlichman C; Ellis MJ
Clin Cancer Res; 2017 Nov; 23(22):6823-6832. PubMed ID: 28874413
[No Abstract] [Full Text] [Related]
14. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.
Miller TW; Rexer BN; Garrett JT; Arteaga CL
Breast Cancer Res; 2011; 13(6):224. PubMed ID: 22114931
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
16. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
Park JH; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim D; Kim SB
Anticancer Res; 2020 Oct; 40(10):5883-5893. PubMed ID: 32988919
[TBL] [Abstract][Full Text] [Related]
17. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.
Zhao S; Liu XY; Jin X; Ma D; Xiao Y; Shao ZM; Jiang YZ
Theranostics; 2019; 9(17):4935-4945. PubMed ID: 31410192
[No Abstract] [Full Text] [Related]
18. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
19. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
20. Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models.
Chakraborty AK; Mehra R; Digiovanna MP
Anticancer Res; 2015 Mar; 35(3):1243-50. PubMed ID: 25750271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
